Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...

Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3,100 new brands collectively earned Rs 1,097 crore, with significant ...

Ms. Jinhua Zhang, Founder, Chairwoman, and CEO of IASO Bio, stated: "We are delighted that the New Drug Application for Equecabtagene Autoleucel has been officially accepted by the Hong Kong ...

The new drug combination reduced the risk of disease progression or death by 27%, with patients on the Calquence combination living an average of 66.4 months without their cancer getting worse ...

Ms. Jinhua Zhang, Founder, Chairwoman, and CEO of IASO Bio, stated: "We are delighted that the New Drug Application for Equecabtagene Autoleucel has been officially accepted by the Hong Kong ...

The FDA requested new and updated information and clarifications related to drug substance, drug product, manufacturing, and microbiology. The FDA did not express concern about the stability of the ...

New blinded preliminary BRTX-100 data described this past Saturday at prestigious “2025 Winners in Industry Innovations in MSK Health” presentation – – Among other positive preliminary data analyses, ...

Eton Pharmaceuticals, Inc. announced that the FDA has extended the PDUFA goal date for its New Drug Application (NDA) for ET-400 to May 28, 2025, allowing the agency additional time to review ...

New drug shows promise in reversing memory loss for early Alzheimer's patients. ScienceDaily . Retrieved February 28, 2025 from www.sciencedaily.com / releases / 2025 / 02 / 250204141840.htm ...

Whoopi Goldberg warned about an AI advertisement that's using her image to sell weight-loss drugs.

According to Lambert, the wound dressings are on track for regulatory submission as medical devices, which, if approved, offers a faster pathway to market compared to new drug applications.